First-line treatment of panitumumab (Pmab) plus FOLFOX or Pmab plus FOLFIRI demonstrated improved outcomes in patients with wild-type-KRAS metastatic colorectal cancer (CRC) and liver-limited disease.
We report a case of a 41 year-old man with a KRAS wild type CRC with multiple liver metastases who received first-line Pmab plus FOLFOX4 in 2014. After 5 cycles, remarkable tumor shrinkage was observed in the liver as only one reduced sized metastasis could be detected. Liver metastasectomy and after a definitive radiotherapy for the primary tumor, rectosigmoideal resection were performed. Half, then one year later two more liver metastasectomies were needed because of recurrency of the liver lesions.
The patient has been tumor-free for 1.5 years due to the first-line Pmab plus FOLFOX4 treatment followed by well decided surgical resections. We consider this case as a successful treatment with a 40 months follow-up, exceeding the literature median OS data of 23.9 months.